Hello Everyone, We are excited to announce that ResearchDx will be attending ASCO 2023! We will be exhibiting at booth # 13029 from June 3-5. Come stop by to learn how we can help your company expand and incentivise its companion diagnostics pipeline.
Hemophilia—The Royal Disease
Our CAP/CLIA certified lab, PacificDx is partnered with CHOC (Children’s Hospital of Orange County) to identify rare inherited blood disorders in infants and mothers to improve their quality of life. ____________________________________________________________________________________________________________________________________________________ The last royal family of Russia was speculated to be plagued with the “royal bleeding disease” passed down by Queen Victoria of England who […]
trio-smart®: The New Breathtaking Technology
PacificDX is the only lab certified to run trio-Smart, a breath test developed by Gemelli. trio-smart measures the standard H2, CH4, and CO2 and is the only BT that also measures hydrogen sulfide. You are at a fancy dinner party wearing your favorite dress and after the delicious meal, you are conversing with an old friend […]
ResearchDx Partners with Lucid Diagnostics for First DNA Methylation Test for Barrett’s Esophagus
As Lucid Diagnostics’ commercial diagnostic laboratory partner, the new EsoGuard esophageal DNA laboratory-developed test (LDT) was developed and completed CLIA and CAP certification at ResearchDx’s premier molecular laboratory, PacificDx. The first of its kind, this non-invasive DNA test was designed to detect the presence of dysplastic and non-dysplastic Barrett’s Esophagus (BE) and esophageal adenocarcinoma (EAC) […]
Negative Gluten ID Test Results can ‘Rule Out’ Celiac Disease in High Risk Populations
Brief: First degree relatives of individuals with celiac disease are at elevated risk for developing a similarly severe gluten intolerance disorder. However, a quick screening test for the genetic alterations responsible for encoding gluten recognition immune receptors can rule out celiac disease risk in these individuals. Developed by Targeted Genomics, the DNA-based, non-invasive Gluten ID […]
Molecular Medicine Tri-Con Meeting
Irvine, CA — Jan 28, 2020 — PacificDx will attend the Molecular Medicine Tri-Con Meeting in San Francisco California, March 1–4. Please visit our booth #600, or call us at 866.225.9195 or 949.812.6902 to set up a consultation at the show.
Gluten ID — New, Simple, Non-Invasive DNA Test can ‘Rule-Out’ Inherited Celiac Disease
Everyone enjoys the aroma and taste of fresh bread from the oven, and of course, slathered with butter— but, if you are the ‘one’ in every 100 people who has been diagnosed with celiac disease or among the estimated 30% of the population who are genetically at risk for gluten intolerance, the downstream health effects […]
Blood-Based Biomarkers Discriminate IBS from IBD with High Degree of Certainty in Patients with Chronic Diarrhea
Brief: Two blood-based biomarkers, cytolethal distending toxin B (CdtB) and anti-vinculin, have been substantively linked with the occurrence of diarrhea-predominant forms of irritable bowel syndrome (IBS). As a result, an ELISA-based diagnostic test developed by Gemelli Biotech is now able to “rule-in” an IBS diagnosis while “ruling-out” irritable bowel disease (IBD) based on elevated biomarker […]
ibs-smart™—The New Blood Test That Confirms an Irritable Bowel Syndrome Diagnosis
It’s been a long and difficult road for many who suffer from a disease they neither understand nor have been able to acquire a diagnosis. There is a significant crossover of signs and symptoms among gastrointestinal conditions and diseases that cause a burdensome diagnostic journey for the person trying to determine the cause of their […]
Association for Molecular Pathology (AMP)
Irvine, CA — July 18, 2019 — PacificDx will attend the Association of Molecular Pathology (AMP) in Baltimore, Maryland November 7–9, 2019. Please visit our booth #2967, or call us at 866.225.9195 or 949.812.6902 to set up a consultation at the show.